Sarepta Therapeutics Inc (NASDAQ:SRPT) – SunTrust Banks lowered their Q1 2018 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued on Wednesday. SunTrust Banks analyst E. Nash now forecasts that the biotechnology company will post earnings per share of ($0.38) for the quarter, down from their previous estimate of ($0.16). SunTrust Banks currently has a “Buy” rating and a $76.00 target price on the stock. SunTrust Banks also issued estimates for Sarepta Therapeutics’ Q2 2018 earnings at ($0.30) EPS, Q3 2018 earnings at ($0.31) EPS, Q4 2018 earnings at ($0.15) EPS, FY2018 earnings at ($1.14) EPS, FY2019 earnings at $0.97 EPS, FY2020 earnings at $6.44 EPS, FY2021 earnings at $7.44 EPS and FY2022 earnings at $10.68 EPS.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The company had revenue of $57.30 million for the quarter, compared to analyst estimates of $57.33 million. During the same period last year, the company posted ($0.71) earnings per share. The business’s revenue for the quarter was up 961.1% on a year-over-year basis.
Other analysts have also issued research reports about the company. Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $75.00 price objective on the stock. HC Wainwright set a $75.00 price objective on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Oppenheimer restated a “buy” rating and issued a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Finally, Nomura upped their price objective on Sarepta Therapeutics to $96.00 and gave the company a “buy” rating in a research note on Friday, March 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating to the company. Sarepta Therapeutics presently has a consensus rating of “Buy” and an average target price of $70.55.
Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $79.10 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96. The stock has a market capitalization of $5,110.00, a P/E ratio of -98.88 and a beta of 1.51. Sarepta Therapeutics has a 52 week low of $28.14 and a 52 week high of $80.23.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in Sarepta Therapeutics by 0.9% during the 4th quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock worth $349,773,000 after acquiring an additional 58,433 shares during the period. Fred Alger Management Inc. increased its stake in Sarepta Therapeutics by 10.5% during the 4th quarter. Fred Alger Management Inc. now owns 1,581,525 shares of the biotechnology company’s stock worth $87,996,000 after acquiring an additional 149,712 shares during the period. Jennison Associates LLC increased its stake in Sarepta Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after acquiring an additional 6,357 shares during the period. Eagle Asset Management Inc. increased its stake in Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after acquiring an additional 207,810 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC increased its stake in Sarepta Therapeutics by 63.4% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock worth $48,564,000 after acquiring an additional 338,737 shares during the period. Institutional investors own 85.14% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Q1 2018 EPS Estimates for Sarepta Therapeutics Inc Cut by SunTrust Banks (SRPT)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/03/13/q1-2018-eps-estimates-for-sarepta-therapeutics-inc-cut-by-suntrust-banks-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.